Insights

Gathering insights about BLUEPRINT…

Similar companies to BLUEPRINT

BLUEPRINT Tech Stack

BLUEPRINT uses 8 technology products and services including WordPress, Google Cloud, React, and more. Explore BLUEPRINT's tech stack below.

WordPress
Content Management System
Google Cloud
Infrastructure As A Service
React
Javascript Frameworks
Lodash
Javascript Libraries
Polyfill
Javascript Libraries
Google Maps
Maps
Bootstrap
UI Frameworks
Nginx
Web Servers

Media & News

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P.
Dec 18, 2024 | www.prnewswire.com
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT -- CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes.
Dec 07, 2024 | www.prnewswire.com
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Nov 29, 2024 | www.zacks.com
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.
Nov 15, 2024 | seekingalpha.com
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
Nov 14, 2024 | www.benzinga.com
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Oct 31, 2024 | www.zacks.com
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.
Oct 30, 2024 | seekingalpha.com

BLUEPRINT's Email Address Formats

BLUEPRINT uses at least 1 format(s):

BLUEPRINT Email Formats	Example	Percentage
FLast@blueprinthcre.com	JDoe@blueprinthcre.com	87%
First@blueprinthcre.com	John@blueprinthcre.com	9%
First.Last@blueprinthcre.com	John.Doe@blueprinthcre.com	2%
FirstLast@blueprinthcre.com	JohnDoe@blueprinthcre.com	2%

Frequently Asked Questions

Where is BLUEPRINT's headquarters located?

BLUEPRINT's main headquarters is located at 191 N. Wacker Drive Suite 1600 Chicago, Illinois 60606 US. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is BLUEPRINT's phone number?

You can contact BLUEPRINT's main corporate office by phone at

+1-312-300-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BLUEPRINT's stock symbol?

BLUEPRINT is a publicly traded company; the company's stock symbol is BPMC.

What is BLUEPRINT's official website and social media links?

BLUEPRINT's official website is blueprinthcre.com and has social profiles on LinkedIn.

How much revenue does BLUEPRINT generate?

As of July 2024, BLUEPRINT's annual revenue reached $3.8M.

How many employees does BLUEPRINT have currently?

As of July 2024, BLUEPRINT has approximately 57 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer & Co-Founder: B. F.Chief Vision Officer And Founding Partner: J. G.Head Of Behavioral Healthcare: A. S.. Explore BLUEPRINT's employee directory with LeadIQ.

What industry does BLUEPRINT belong to?

BLUEPRINT operates in the Real Estate industry.

What technology does BLUEPRINT use?

BLUEPRINT's tech stack includes WordPressGoogle CloudReactLodashPolyfillGoogle MapsBootstrapNginx.

What is BLUEPRINT's email format?

BLUEPRINT's email format typically follows the pattern of . Find more BLUEPRINT email formats with LeadIQ.

When was BLUEPRINT founded?

BLUEPRINT was founded in 2013.

BLUEPRINT

Real EstateIllinois, United States51-200 Employees

Blueprint was founded in 2013 with a mission to elevate healthcare real estate advisory through collaboration and data. Blueprint is now the most active advisory firm in seniors housing and skilled nursing, as well as a market leader within other healthcare real estate subsegments.  With a proven track record of $13 billion in transaction volume, the Blueprint model rests on the unique combination of broad market coverage and unrivaled analytics.  Blueprint has comprehensive industry expertise in skilled nursing, seniors housing, medical outpatient, and behavioral healthcare.

Join our team: BlueprintHCRE.com/Careers